NIKKEI 225
37,068.35 -1,011.35 (-2.66%) HANG SENG
16,209.46 -176.41 (-1.08%) CRUDE OIL
83.88 +1.15 (+1.39%) GOLD FUTURES
2,396.70 -1.30 (-0.05%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
50,495.85 +1,436.06 (+2.93%)
Chimerix, Inc. (CMRX)
After hours:
| Previous close | 0.9040 |
| Open | 0.9100 |
| Bid | 0.8949 x 200 |
| Ask | 0.9602 x 200 |
| Day's range | 0.8921 - 0.9400 |
| 52-week range | 0.8800 - 1.5700 |
| Volume | |
| Avg. volume | 426,762 |
| Market cap | 83.171M |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to four new employees of non-statutory stock options to purchase up to a total of 223,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule
- GlobeNewswire
Chimerix Appoints Marc D. Kozin to Board of Directors
Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy ExperienceDURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effe
- GlobeNewswire
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 – – Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology – – $204 Million in Cash and Equivalents at December 31, 2023 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients faci
